000 01113 a2200313 4500
005 20250513053717.0
264 0 _c19950105
008 199501s 0 0 eng d
022 _a0271-8235
024 7 _a10.1055/s-2008-1041066
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aRichman, D P
245 0 0 _aMyasthenia gravis: pathogenesis and treatment.
_h[electronic resource]
260 _bSeminars in neurology
_cJun 1994
300 _a106-10 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
650 0 4 _aAnimals
650 0 4 _aCombined Modality Therapy
650 0 4 _aDisease Models, Animal
650 0 4 _aHumans
650 0 4 _aImmunization
_xadverse effects
650 0 4 _aMyasthenia Gravis
_ximmunology
650 0 4 _aNeuromuscular Junction
_ximmunology
650 0 4 _aReceptors, Nicotinic
_ximmunology
650 0 4 _aSynaptic Transmission
_ximmunology
700 1 _aAgius, M A
773 0 _tSeminars in neurology
_gvol. 14
_gno. 2
_gp. 106-10
856 4 0 _uhttps://doi.org/10.1055/s-2008-1041066
_zAvailable from publisher's website
999 _c7984154
_d7984154